FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Fudan University
University Hospital, Akershus
Duke University
City of Hope Medical Center
UNICANCER
Memorial Sloan Kettering Cancer Center
Federation Francophone de Cancerologie Digestive
Memorial Sloan Kettering Cancer Center
UNICANCER
Ruijin Hospital
Federation Francophone de Cancerologie Digestive
OHSU Knight Cancer Institute
The First Hospital of Jilin University
Asan Medical Center
Jiangsu Cancer Institute & Hospital
Hoosier Cancer Research Network
National Cancer Institute, Naples
Ludwig-Maximilians - University of Munich
Brown University
GSO Global Clinical Research BV
Fox Chase Cancer Center
UNICANCER
SCRI Development Innovations, LLC
Translational Oncology Research International
AIO-Studien-gGmbH
UNICANCER
University of Florida
Odense University Hospital
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Herlev Hospital
Massachusetts General Hospital
The University of Hong Kong
NYU Langone Health
Asan Medical Center
Abramson Cancer Center at Penn Medicine
Dong-A University Hospital
University Health Network, Toronto
University of California, Davis
Peking University
UNC Lineberger Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Huashan Hospital
Sixth Affiliated Hospital, Sun Yat-sen University
M.D. Anderson Cancer Center
Samsung Medical Center
Vanderbilt University
University of Pittsburgh
Medical College of Wisconsin
Gustave Roussy, Cancer Campus, Grand Paris